IL22 in Egyptian SLE patients, could it reflect disease activity, skin or renal involvement or is it only an expensive ESR?
Authors:
- Iman Ibrahim El-GazzarIEIman Ibrahim El-Gazzar
- Dina M. Rasheed BahgatDBDina M. Rasheed Bahgat
- Engy M. El KhateebEKEngy M. El Khateeb
Open Access
- 1 January 2017
- journal article
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 39 (1) , 13-18
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Emerging role of interleukin-22 in autoimmune diseasesCytokine & Growth Factor Reviews, 2013
- Amelioration of Experimental Autoimmune Encephalomyelitis by Plumbagin through Down-Regulation of JAK-STAT and NF-κB Signaling PathwaysPLOS ONE, 2011
- Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung diseaseArthritis Research & Therapy, 2011
- Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitisBlood, 2011
- IL-22–Induced Regulatory CD11b+ APCs Suppress Experimental Autoimmune UveitisThe Journal of Immunology, 2011
- Circulating Th17, Th22, and Th1 Cells Are Increased in PsoriasisJournal of Investigative Dermatology, 2010
- MOG35–55 i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathwaysEuropean Journal of Immunology, 2009
- Innate and Adaptive Interleukin-22 Protects Mice from Inflammatory Bowel DiseaseImmunity, 2008
- Systemic IFN‐α drives kidney nephritis in B6.Sle123 miceEuropean Journal of Immunology, 2008
- Shift toward T lymphocytes with a T helper 1 cytokine‐secretion profile in the joints of patients with rheumatoid arthritisArthritis & Rheumatism, 1996